北京中伦（武汉）律师事务所 关于西藏多瑞医药股份有限公司 2025 年第二次临时股东会的 法律意见书 二〇二五年十一月 北京中伦（武汉）律师事务所关于 西藏多瑞医药股份有限公司 2025 年第二次临时股东会的 法律意见书 致：西藏多瑞医药股份有限公司 北京中伦（武汉）律师事务所接受西藏多瑞医药股份有限公司（以下简称"公 司"）的委托，指派本所律师出席了公司 2025 年第二次临时股东会（以下简称"本 次股东会"），并依法进行现场见证。现根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《上市公司股东会规则》（以下简称"《股东会规则》"）、 《深圳证券交易所上市公司股东会网络投票实施细则》（以下简称"《网络投票 实施细则》"）等法律法规和规范性文件以及《西藏多瑞医药股份有限公司章程》 （以下简称"《公司章程》"）的有关规定，就公司本次股东会的有关事宜出具法 律意见书。 本所律师对公司本次股东会的召集、召开程序的合法性、本次股东会召集人 资格的合法有效性、出席本次会议人员资格的合法有效性及会议表决程序、表决 结果的合法有效性，发表法律意见。 本所律师依据对法律意见书出具日以前已经发生或存在的事实的了解及对 ...

Core Viewpoint - Duori Pharmaceutical announced the establishment of a wholly-owned subsidiary, Tibet Ruishengxiang Pharmaceutical Co., Ltd., to optimize its headquarters management functions in response to operational and strategic development needs [2] Group 1 - The establishment of the subsidiary is part of the company's strategy to enhance management efficiency [2] - The new subsidiary is expected to support the company's overall operational goals [2]

Group 1 - Company plans to raise no more than 3.6 billion yuan through a private placement to fund seven projects, including a 500,000 kW green power project in Inner Mongolia [1] - Company has received acceptance for a clinical trial application for its self-developed drug for metastatic pancreatic ductal adenocarcinoma [1] - Company intends to establish a joint venture to implement a high-quality gallium arsenide chip construction project with a total investment of 272 million yuan [2] Group 2 - Company reported a revenue of 142 million yuan from pig sales in October, with a total sales volume of 162,800 pigs [3] - Company signed an annual procurement contract to supply 870,000 tons of electrolyte products from 2026 to 2028 [5] - Company plans to reduce its shareholding by up to 3% through various trading methods [7] Group 3 - Company intends to purchase 100 hydrogen fuel cell vehicles for a total price of 78.32 million yuan [9] - Company plans to acquire a 51% stake in a semiconductor equipment company for 510 million yuan [10] - Company has regained eligibility to participate in military procurement activities after being removed from the banned list [12] Group 4 - Company plans to establish a joint venture with state-owned funds for rural development with a total registered capital of 2.87 billion yuan [14] - Company reported a revenue of 1.918 billion yuan from pig sales in October, with a significant year-on-year increase [16][17] - Company plans to distribute a cash dividend of 0.01 yuan per share, totaling 7.9801 million yuan [18] Group 5 - Company has submitted an application for H-share listing on the Hong Kong Stock Exchange [19] - Company received approval for its convertible bond issuance application [20] - Company plans to establish a wholly-owned subsidiary with an investment of 70 million yuan focused on innovative medical research [22] Group 6 - Company reported a 33.87% year-on-year increase in sales volume for October [26] - Company has received a product designation from a leading new energy vehicle brand, with an expected total revenue of approximately 470 million yuan [28] - Company has initiated a key Phase III clinical trial for an innovative eye drop treatment for moderate to severe dry eye syndrome [30] Group 7 - Company reported a total automobile sales volume of 170,700 units in October, a year-on-year decrease of 8.1% [30] - Company plans to invest 16 million USD in establishing a production base in Vietnam [33] - Company has received a warning letter from the regulatory authority due to a breach of commitment by its controlling shareholder [52]

Core Viewpoint - Duori Pharmaceutical (301075.SZ) has established a wholly-owned subsidiary, Tibet Ruishengxiang Pharmaceutical Co., Ltd., to optimize its headquarters management functions and align with its long-term development strategy and shareholder interests [1] Group 1 - The new subsidiary will engage in the distribution of pharmaceuticals and medical devices [1] - The establishment of the subsidiary is part of the company's strategic development needs [1] - This move is aimed at enhancing the management efficiency of the company's headquarters [1]

Core Viewpoint - Duori Pharmaceutical (301075.SZ) has announced the establishment of a wholly-owned subsidiary, Tibet Ruishengxiang Pharmaceutical Co., Ltd., with a registered capital of 2 million yuan to optimize the management functions of its headquarters based on operational and strategic development needs [1] Group 1 - The company aims to enhance its management capabilities through the formation of the new subsidiary [1] - The registered capital for the new subsidiary is set at 2 million yuan [1]

Core Viewpoint - Duori Pharmaceutical (301075.SZ) has announced the establishment of a wholly-owned subsidiary, Tibet Ruishengxiang Pharmaceutical Co., Ltd., with a registered capital of 2 million yuan to optimize its headquarters management functions based on operational and strategic development needs [1]. Group 1 - The company is focusing on enhancing its management capabilities through the formation of a new subsidiary [1]. - The registered capital for the new subsidiary is set at 2 million yuan [1].

西藏多瑞医药股份有限公司 证券代码：301075 证券简称：多瑞医药 公告编号：2025-099 二、成立全资子公司基本情况 1、公司名称：西藏瑞升祥医药有限公司 2、注册资本：200 万元 3、公司类型：有限责任公司（非自然人投资或控股的法人独资） 关于成立全资子公司的公告 4、公司住所：西藏自治区昌都市经济开发区 A 区（创业大道 9 号）一号办公楼二楼 A07 号 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、对外投资概述 根据公司经营及战略发展的需要，为优化公司总部管理职能，西 藏多瑞医药股份有限公司成立全资子公司西藏瑞升祥医药有限公司。 根据公司《公司章程》《对外投资管理制度》等相关规定，本次 对外投资事项在公司总经理的决策权限内，无需提交董事会、股东会 审议。 本次对外投资不涉及关联交易，也不构成《上市公司重大资产重 组管理办法》规定的重大资产重组。 5、出资方及出资比例：西藏多瑞医药股份有限公司持股 100% 6、经营范围：许可项目：药品批发；第三类医疗器械经营；食 品生产；食品销售；药品进出口；保健食品生产；特殊医学用途配方 食品生产；药 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2025-098 西藏多瑞医药股份有限公司 关于向控股子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 西藏多瑞医药股份有限公司（以下简称"公司"）于 2025 年 10 月 13 日召开第二届董事会第二十三次会议、于 2025 年 10 月 30 日召开 2025 年第一次临时股东会，审议通过了《关于向控股子公司增加担 保额度的议案》，同意公司为控股子公司湖北鑫承达化工有限公司（以 下简称"鑫承达"）、四川多瑞药业有限公司（以下简称"四川多瑞"） 合计增加不超过 13,000 万元人民币的连带责任保证担保额度。鑫承 达少数股东按出资比例提供同等担保或者反担保；四川多瑞为公司控 股子公司，公司能够控制其经营及管理，有效地监督和管控为其提供 的担保，担保风险可控，不会损害上市公司利益，因此其少数股东不 提供同等担保或者反担保。具体内容详见公司于 2025 年 10 月 14 日 在巨潮资讯网（www.cninfo.com.cn）披露的相关公告。 二、担保进展情况 近日 ...

Core Viewpoint - Duori Pharmaceutical, established in December 2016 and listed on the Shenzhen Stock Exchange in September 2021, focuses on the research and development of chemical drug formulations and has several core technologies in this field [1] Business Performance - For Q3 2025, Duori Pharmaceutical reported revenue of 137 million, ranking 103rd among 110 companies in the industry, significantly lower than the industry leader, East China Pharmaceutical, which had revenue of 32.664 billion, and the industry average of 2.8 billion [2] - The net profit for the same period was -113 million, placing the company 96th in the industry, while the top performer, Hengrui Medicine, achieved a net profit of 5.76 billion, with the industry average at 299 million [2] Financial Ratios - As of Q3 2025, Duori Pharmaceutical's debt-to-asset ratio was 55.73%, an increase from 28.40% in the previous year and above the industry average of 35.26%, indicating increased debt pressure [3] - The gross profit margin for Q3 2025 was 4.63%, a significant drop from 40.75% in the previous year and below the industry average of 57.17%, reflecting weak profitability [3] Executive Compensation - The chairman and general manager, Deng Yong, received a salary of 609,000 in 2024, a decrease of 31,200 from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 16.60% to 6,361, while the average number of circulating A-shares held per account increased by 19.90% to 12,600 [5]

北京中伦（武汉）律师事务所 关于西藏多瑞医药股份有限公司 2025 年第一次临时股东大会的 法律意见书 北京中伦（武汉）律师事务所接受西藏多瑞医药股份有限公司（以下简称"公 司"）的委托，指派本所律师出席了公司 2025 年第一次临时股东大会（以下简 称"本次股东大会"），并依法进行现场见证。现根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《上市公司股东会规则》（以下简称"《股东会 规则》"）、《深圳证券交易所上市公司股东会网络投票实施细则》（以下简称 "《网络投票实施细则》"）等法律法规和规范性文件以及《西藏多瑞医药股份 有限公司章程》（以下简称"《公司章程》"）的有关规定，就公司本次股东大 会的有关事宜出具法律意见书。 本所律师对公司本次股东大会的召集、召开程序的合法性、本次股东大会召 集人资格的合法有效性、出席本次会议人员资格的合法有效性及会议表决程序、 表决结果的合法有效性，发表法律意见。 二〇二五年十月 北京中伦（武汉）律师事务所关于 西藏多瑞医药股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：西藏多瑞医药股份有限公司 本所律师依据对法律意见书出具日以前已经发生或存在的事 ...